Genes may determine who gets hooked or psychotic from cannabis

NCT ID NCT06058702

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates how a person's genetic makeup influences their response to cannabis, including risk for addiction and psychosis. Healthy adults aged 21-60 receive either a very low or medium dose of THC (the active ingredient in cannabis) or a placebo intravenously. Researchers measure changes in mood, perception, thinking, and symptoms to see if certain genes predict stronger reactions. The goal is to better understand why some people develop cannabis use disorder or schizophrenia-related symptoms after using cannabis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Delta-9-THC (active ingredient in cannabis) given intravenously at very low and medium doses, compared to placebo
What this could lead to
If successful, this research could help identify genetic factors that make some people more vulnerable to cannabis addiction or psychosis, potentially guiding personalized prevention or treatment strategies.
What could go wrong
This is an early-phase study with a small sample, so findings may not apply broadly. The genetic links are complex and may not lead to clear clinical applications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West Haven Veterans Affairs Medical Center

    RECRUITING

    West Haven, Connecticut, 06516, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.